| Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer CN Papandreou, DD Daliani, D Nix, H Yang, T Madden, X Wang, CS Pien, ... Journal of Clinical Oncology 22 (11), 2108-2121, 2004 | 535 | 2004 |
| Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial SM Tu, RE Millikan, B Mengistu, ES Delpassand, RJ Amato, LC Pagliaro, ... The Lancet 357 (9253), 336-341, 2001 | 471 | 2001 |
| Platinum-based chemotherapy for variant castrate-resistant prostate cancer AM Aparicio, AL Harzstark, PG Corn, S Wen, JC Araujo, SM Tu, ... Clinical cancer research 19 (13), 3621-3630, 2013 | 438 | 2013 |
| Multimodality management of urachal carcinoma: the MD Anderson Cancer Center experience AO Siefker-Radtke, J Gee, YU Shen, S Wen, D Daliani, RE Millikan, ... The Journal of urology 169 (4), 1295-1298, 2003 | 374 | 2003 |
| Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and … R Millikan, C Dinney, D Swanson, P Sweeney, JY Ro, TL Smith, ... Journal of Clinical Oncology 19 (20), 4005-4013, 2001 | 367 | 2001 |
| Focus on bladder cancer CPN Dinney, DJ McConkey, RE Millikan, X Wu, M Bar-Eli, L Adam, ... Cancer cell 6 (2), 111-116, 2004 | 341 | 2004 |
| Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle–control genes X Wu, J Gu, HB Grossman, CI Amos, C Etzel, M Huang, Q Zhang, ... The American Journal of Human Genetics 78 (3), 464-479, 2006 | 329 | 2006 |
| Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the MD Anderson cancer experience AO Siefker-Radtke, CP Dinney, NA Abrahams, C Moran, YU Shen, ... The Journal of urology 172 (2), 481-484, 2004 | 304 | 2004 |
| A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy … DJ McConkey, W Choi, YU Shen, IL Lee, S Porten, SF Matin, AM Kamat, ... European urology 69 (5), 855-862, 2016 | 274 | 2016 |
| The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function DB Mendel, RE Schreck, DC West, G Li, LM Strawn, SS Tanciongco, ... Clinical cancer research 6 (12), 4848-4858, 2000 | 272 | 2000 |
| The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma AM Kamat, JR Gee, CPN Dinney, HB Grossman, DA Swanson, ... The Journal of urology 175 (3), 881-885, 2006 | 249 | 2006 |
| Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinoma SF Matin, V Margulis, A Kamat, CG Wood, HB Grossman, GA Brown, ... Cancer 116 (13), 3127-3134, 2010 | 243 | 2010 |
| Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer CN Sternberg, SM Donat, J Bellmunt, RE Millikan, W Stadler, P De Mulder, ... Urology 69 (1), 62-79, 2007 | 242 | 2007 |
| Dose-finding with two agents in phase I oncology trials PF Thall, RE Millikan, P Mueller, SJ Lee Biometrics 59 (3), 487-496, 2003 | 224 | 2003 |
| The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy K Inoue, JW Slaton, T Karashima, C Yoshikawa, T Shuin, P Sweeney, ... Clinical Cancer Research 6 (12), 4866-4873, 2000 | 219 | 2000 |
| Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma E Jonasch, CG Wood, SF Matin, SM Tu, LC Pagliaro, PG Corn, A Aparicio, ... Journal of clinical oncology 27 (25), 4076, 2009 | 215 | 2009 |
| Refining patient selection for neoadjuvant chemotherapy before radical cystectomy SH Culp, RJ Dickstein, HB Grossman, SM Pretzsch, S Porten, ... The Journal of urology 191 (1), 40-47, 2014 | 199 | 2014 |
| Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival D Leibovici, HB Grossman, CP Dinney, RE Millikan, S Lerner, Y Wang, ... Journal of clinical oncology 23 (24), 5746-5756, 2005 | 195 | 2005 |
| Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center SP Lynch, Y Shen, A Kamat, HB Grossman, JB Shah, RE Millikan, ... European urology 64 (2), 307-313, 2013 | 183 | 2013 |
| Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer AO Siefker-Radtke, AM Kamat, HB Grossman, DL Williams, W Qiao, ... Journal of Clinical Oncology 27 (16), 2592, 2009 | 180 | 2009 |
